Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

NCT01353222 is registered in ClinicalTrials.gov with Dendreon as lead sponsor.

NCT NCT01353222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01353222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Lead sponsor
Dendreon
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2011
Completion date
July 31, 2015
Enrollment
142 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma